These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10975752)

  • 1. Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
    Boucher E; Guyader D; Jacquelinet S; Andre P; Mendler MH; Turlin B; Canva V; Nousbaum JB; Bernard PH; Nouel O; Raabe JJ; Dao T; Gasser P; Verger P; Boutin J; Bergerault P; Joram F; Colmar P; Messner M; Brissot P; Deugnier Y
    Dig Liver Dis; 2000; 32(1):29-33. PubMed ID: 10975752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial.
    Abdelmalek MF; Harrison ME; Gross JB; Poterucha JJ; Gossard AA; Spivey JR; Rakela J; Lindor KD
    J Clin Gastroenterol; 1998 Mar; 26(2):130-4. PubMed ID: 9563925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
    Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
    Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
    Berg T; Hoffmann RM; Teuber G; Leifeld L; Lafrenz M; Baumgarten R; Spengler U; Zeuzem S; Pape GR; Hopf U
    Liver; 2000 Dec; 20(6):427-36. PubMed ID: 11169056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
    Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
    J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
    Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
    J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
    Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
    Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C.
    Younossi ZM; Perrillo RP
    Semin Liver Dis; 1999; 19 Suppl 1():95-102. PubMed ID: 10349697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
    Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
    J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients--results of a randomized, prospective, pilot study.
    Ullerich H; Avenhaus W; Poremba C; Domschke W; Menzel J
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2107-14. PubMed ID: 12452944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
    Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.